Analysis of Overall Gene Expression Induced by Amphetamine and Phencyclidine: Novel Targets for the Treatment of Drug Psychosis and Schizophrenia

Author: Ito, C.

Source: Current Pharmaceutical Design, Volume 8, Number 2, 1 January 2002 , pp. 147-153(7)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Although the etiology of drug psychosis or schizophrenia is still unknown, molecular and biochemical researches have recently made significant advances in the search for the candidate genes of these disorders. Among such studies are animal models of drug psychosis or schizophrenia such as amphetamine-induced behavioral sensitization or phencyclidine-treated animals. In this review, it is suggested that amphetamine or phencyclidine change the gene expressions related to not only neurotransmistter systems such as dopamine or glutamic acid, transcription factors, cell proliferation, apoptosis, cell adhesion, but also the synapse. These alterable gene expressions may lead to the discovery of candidate genes of drug psychosis or schizophrenia and thus to novel antipsychotics.

Keywords: Amphetamine; Phencyclidine; amphetamine-like psychostimulant

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612023396528

Publication date: 2002-01-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.